India bans 80 more FDCs, calling them 'irrational' and 'unjustified'
The Indian Union Health Ministry has banned 80 more fixed-dose combination (FDC) drugs which include antibiotics, painkillers, and medicines used for treating hypertension and anxiety, reports The Pharma Letter’s India correspondent.
India reportedly boasts around 2,000 FDCs, four times more that what is available in the USA. The Indian government's intent to ban another 80 drugs is part of its ongoing crackdown against what it terms are 'irrational' medications.
According to a notification issued by the ministry on January 11, the drugs banned include antibiotics like Cefglobe OZ, Taxim -OZ, drugs used for treating bacterial and fungal infections, hypertension drugs Telipril H and Loram H and anti-anxiety drug Resta, which is a combination of paracetamol and alprazolam.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze